# Official Website: Batu Biologics

**Type:** source
**Status:** Useful
**Confidence:** Low
**Source Type:** Official Website
**URL:** Unknown
**Publisher:** Batu Biologics
**Accessed:** 2026-06-19
**Updated:** 2026-06-19

## Summary

No confirmed public website URL for Batu Biologics has been identified. The company is described as a University of Utah Technology Licensing Office spinout in the immuno-oncology space, targeting tumor vasculature. Public documentation of the company's mechanism, team, funding, or pipeline is very limited. Claims in the venture page draw on the general scientific context of anti-angiogenic oncology and the U of U spinout ecosystem rather than company-specific primary sources.

## Useful Claims

- Batu Biologics is listed as part of the University of Utah Technology Licensing Office startup portfolio.
- The company's stated approach targets tumor vasculature as an immuno-oncology strategy, described with "Achilles Heel of cancer" framing.
- Location is Salt Lake City, UT.
- Stage is preclinical; funding is unknown.

## Reliability Notes

No official website could be confirmed. All claims in the associated venture page should be treated as low-confidence until a primary source is identified. The anti-angiogenesis scientific context (Folkman hypothesis, bevacizumab approval) is well-established and high-confidence; claims specific to Batu Biologics' differentiation and mechanism are not verified from a primary source.

## Related Pages

- [Batu Biologics](batu-biologics.md)